Law360, New York (June 26, 2006, 12:00 AM EDT) -- In a case that could influence how the U.S. Federal Trade Commission rules on future settlement agreements over generic drugs, Bristol-Myers Squibb, Sanofi-Aventis and Apotex have altered their settlement over the blockbuster blood thinner Plavix, the companies said.
The companies agreed to move the date for a generic version up three months. Canadian drug maker Apotex can sell its generic version starting on June 1, 2011 instead of on Sept. 17, 2011, according to Bristol-Myers, the U.S. partner of French pharmaceutical giant Sanofi-Aventis, and Apotex....
Plavix Settlement Updated To Appease FTC
To view the full article, register now.
Try Law360 FREE for seven days
Already a subscriber? Click here to login
